Alumis (ALMS) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Alumis (ALMS) over the past year, losing 0.5% versus a loss of 45.8%. Crescent Biopharma is the larger company by market cap ($543.2 million vs $514.1 million), about 1.1 times the size. Alumis converts more of its revenue into profit, with a net margin of -1011.7% versus -1419.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | CBIO |
|---|---|---|
| Share price | $3.96 | $13.00 |
| Market cap | $514.09M | $543.21M |
| 1-day change | -8.55% | +0.70% |
| YTD return | -59.43% | +9.61% |
| 1-year return | -45.75% | -0.46% |
| 5-year return | — | -92.74% |
| EPS (TTM) | $-3.53 | $-7.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $10.84M |
| Net income (latest FY) | $-243.32M | $-153.94M |
| Operating margin | -1886.92% | -1407.52% |
| Net margin | -1011.75% | -1419.61% |
| 52-week high | $31.35 | $27.41 |
| 52-week low | $3.94 | $8.72 |
| Distance from 52-week high | -87.37% | -52.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +540.91% | +148.69% |
| Average volume | 2.87M | 361.17K |
| Shares outstanding | 129.82M | 38.90M |
| Employees | 251 | 80 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed ALMS by 45.3 percentage points over the past year.
- Alumis is more profitable, keeping -1011.7 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
ALMS vs CBIO FAQ
Which is bigger, Alumis or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $514.09M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or CBIO?
CBIO returned -0.46% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.